Semaglutide and Kidney Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease

In the FLOW trial, once-weekly semaglutide reduced the risk of major kidney disease events and death from cardiovascular causes by roughly a quarter in patients with type 2 diabetes and chronic kidney disease.